REMODULIN 1 MG
TREPROSTINIL (TREPROSTINIL SODIUM) : 1 MG · DIN 02246552 · UNITED THERAPEUTICS CORPORATION
Health Canada status: MARKETED
What is REMODULIN?
REMODULIN 1 MG contains TREPROSTINIL (TREPROSTINIL SODIUM) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02246552, held by UNITED THERAPEUTICS CORPORATION, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 07-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is REMODULIN used for?
Long-term, subcutaneous or intravenous treatment of pulmonary arterial hypertension (PAH) in NYHA Class III and IV patients who did not respond adequately to conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02246552 |
|---|---|
| Brand name | REMODULIN |
| Generic / active ingredient | TREPROSTINIL (TREPROSTINIL SODIUM) : 1 MG |
| Manufacturer | UNITED THERAPEUTICS CORPORATION |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B01AC21 TREPROSTINIL |
| AHFS class | 48:48.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Oct-2005 |
| Original market date | 2004-04-30 00:00:00 |
How is it administered?
Initial: 1.25 ng/kg/min. Increase by 1.25 ng/kg/min per week for 4 weeks, then 2.5 ng/kg/min per week. Administered via continuous SC or IV infusion. Avoid abrupt withdrawal.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
During use, a single reservoir of undiluted Remodulin can be administered up to 72 hours at 37°C. (General storage not in provided snippet).
How is it supplied?
Not explicitly detailed in provided text beyond vial strengths; typically multi-dose vials.
Contraindications
Known hypersensitivity to the drug, any of its excipients, or to structurally related compounds.
Warnings and precautions
Potent vasodilator. Abrupt withdrawal may cause worsening of PAH. IV route associated with risk of fatal blood stream infections/sepsis; SC is preferred. Use caution in hepatic/renal impairment.
What can be used instead?
Other Canadian products sharing ATC code B01AC21 TREPROSTINIL. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| REMODULIN | 10 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246555 |
| REMODULIN | 2.5 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246553 |
| REMODULIN | 5 MG | SOLUTION | UNITED THERAPEUTICS CORPORATION | MARKETED | DIN 02246554 |
| TREPROSTINIL INJECTION | 1 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523841 |
| TREPROSTINIL INJECTION | 10 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523884 |
| TREPROSTINIL INJECTION | 2.5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523868 |
| TREPROSTINIL INJECTION | 5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02523876 |
Who else supplies TREPROSTINIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TREPROSTINIL appears in 105 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.